Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

A legfontosabb adatok

Ki végzi
Johns Hopkins University
Hol
Baltimore (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2027. ápr.
Várható befejezés
2028. júl.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Psilocybin
A regiszteradat frissítve
2026. február 23.
Miért állt le
This study was de-prioritized in favor of the similar BIPOD-Out protocol due to a combination of practical considerations and expense. There are currently no plans to initiate this protocol.

Ki vehet részt

Életkor
21 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 21-70 years
  • Have given written informed consent
  • Meet diagnostic criteria for OUD
  • No antidepressant medications for approximately 5 half-lives prior to enrollment
  • Not currently taking methadone, buprenorphine or naltrexone
  • Urine toxicology positive for an opioid
  • Has access to stable housing
  • Can read, write, and speak English fluently
  • Be judged by study team clinicians to be at low risk for suicidality
  • Have limited recent use of classic psychedelics (no use in the past year)
  • Expresses a desire for sustained recovery from disordered opioid use

Ki nem vehet részt

  • Currently taking on a daily basis any medications (including herbal substances and supplements) with a central nervous system effect on serotonin, including serotonin-reuptake inhibitors and monoamine oxidase inhibitors; o For individuals who have intermittent or as needed use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose
  • Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or medicines such as phenytoin, regorafenib, eltrombopag
  • Currently taking buprenorphine, methadone, or naltrexone
  • Unable or unwilling to discontinue acid-reducing agents or major metabolizing enzyme inhibitors for 5-half lives prior to the experimental dosing session
  • Cardiovascular conditions: hypertension with resting blood pressure systolic >139 or diastolic >89, angina, heart rate > 99, a clinically significant electrocardiogram abnormality (e.g., atrial fibrillation), Transient Ischemic Attack or Stroke in the last 6 months, peripheral or pulmonary vascular disease, cardiac valvulopathy
  • Epilepsy
  • Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
  • Have a seizure disorder, multiple sclerosis, history of significant head trauma, nervous system tumor, movement disorders or any neurodegenerative condition
  • Morbidly obese (>100 pounds above ideal body weight, or Body Mass Index (BMI) >=40, or BMI >=35 with high blood pressure or diabetes)
  • Allergic to buprenorphine or hydromorphone
  • Current or past history of meeting diagnostic criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Major Depression with psychotic features
  • Have a first or second degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or bipolar I or II disorder
  • For blood samples, the following lab values will be exclusionary: transaminases greater than x2 the upper limit of normal lab reference range, hemoglobin less than 11 g/d, and creatinine clearance < 40 ml/min; Psychiatric Exclusion Criteria:
  • General medical exclusion criteria:
  • Women who are pregnant, nursing, or not practicing an effective means of birth control
  • Body weight < 45 kilograms
  • Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal

Helyszínek itt: Egyesült Államok

  • Johns Hopkins UniversityBaltimore, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

A vizsgálat 2 csoportja

  • High-dose psilocybin + buprenorphineA vizsgált kezelés

    High-dose psilocybin (30 mg) session following standard-of-care buprenorphine induction

    Kezelés: Psilocybin

  • Very low-dose psilocybin + buprenorphineMár használt kezelés, összehasonlításként

    Very low dose psilocybin session (1 mg) following standard-of-care buprenorphine induction

    Kezelés: Psilocybin

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
A regiszteradat frissítve
2026. február 23.